In the news

Using information from a number of continuous data-stream sensors in implantable cardiac devices, Boston Scientific developed the HeartLogic Heart Failure Diagnostic, which can predict heart failure events on average 34 days before they happen. The algorithm alerts doctors of worsening conditions, allowing for earlier intervention and preventative action.

Boston Scientific has put forward real-world safety data gathered on its left atrial appendage occlusion device, the WATCHMAN FLX™. The latest data from Boston Scientific, which spanned more than 16,000 patients with atrial fibrillation not caused by heart valve problems who received the next-generation WATCHMAN FLX device, demonstrated favorable outcomes.

The COVID-19 pandemic has exacerbated the opioid epidemic, and the need for a broader menu of non-opioid treatment options has never been greater. Boston Scientific continues to invest in cutting-edge therapies to help patients and their doctors navigate the ever-changing pain management journey. The Boston Scientific WaveWriter Alpha™ Spinal Cord Stimulation System provides multiple therapy options that can be used in combination to help patients find relief.

Boston Scientific has spent approximately $1 billion buying stakes in about 50 companies globally through its ventures portfolio as a source for new innovation and potential mergers and acquisitions down the road. Since 2018, half of the 16 acquisitions the company completed went through Boston Scientific Ventures, including three of five acquisition targets in 2021.

Baptist Health cardiologist Salil Patel has performed the first procedure in Northeast Florida using the SYNERGY MEGATRON™ stent during a coronary procedure to eliminate blockages in a patient’s heart. The SYNERGY MEGATRON™ is designed for use in large proximal vessels and features architecture with increased strength as well as the ability to expand to 6.0mm in diameter and accommodate tapered vessels.

Mitchell Salloum became the first patient to receive a WATCHMAN™ implant in Wyoming. The Boston Scientific WATCHMAN implant is placed into a patient’s heart in a one-time procedure that may reduce stroke risk for a lifetime in patients with irregular heartbeats.

Many Fortune 500 companies have long-standing, well-oiled programs that often funnel into post-grad development and leadership programs or full-time jobs. For Lauren Nakamura, her marketing internship at Boston Scientific changed the course of her career and gave her confidence and reassurance that she was joining a workplace culture that prioritized work-life integration.

The MODULAR ATP clinical trial has begun to enroll patients to evaluate the safety, performance and effectiveness of Boston Scientific’s mCRM modular therapy system, which includes the Emblem MRI S-ICD and the Empower MPS leadless pacemaker.

*The EMPOWER MPS is an investigational device and limited by U.S. law to investigational use only. It is not available for sale. Some device references are for informational purposes only and are pending CE Mark. Not available in the European Economic Area.

The global medical device manufacturer has maintained operational continuity throughout the pandemic, using clear processes and procedures mixed with a healthy dose of care.

Our innovative TheraSphere™ technology, which increases HCC liver cancer survival rates, may be an effective treatment for other tumors.